[BLUE] bluebird bio, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 64.65 Change: 2.15 (3.44%)
Ext. hours: Change: 0 (0%)

chart BLUE

Refresh chart

Strongest Trends Summary For BLUE

BLUE is in the medium-term down -36% below S&P in 4 months and down -48% below S&P in 1 year. In the long-term down -64% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-7.22 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.14% Sales Growth - Q/Q-0.66% P/E-15.06
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.78% ROE-13.25% ROI
Current Ratio8.11 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-294.47% Net Profit Margin-247.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.46 M Cash From Investing Activities-192.98 M Cash From Operating Activities-24.16 M Gross Profit
Net Profit-24.79 M Operating Profit-24.93 M Total Assets533.82 M Total Current Assets340.84 M
Total Current Liabilities42.01 M Total Debt Total Liabilities59.32 M Total Revenue6.34 M
Technical Data
High 52 week162.45 Low 52 week85.49 Last close89.55 Last change0.87%
RSI22.21 Average true range4.12 Beta1.73 Volume513.89 K
Simple moving average 20 days-5.15% Simple moving average 50 days-13.63% Simple moving average 200 days-29.27%
Performance Data
Performance Week0.95% Performance Month-16.2% Performance Quart-35.78% Performance Half-41.86%
Performance Year-28.98% Performance Year-to-date-9.73% Volatility daily2.57% Volatility weekly5.75%
Volatility monthly11.78% Volatility yearly40.8% Relative Volume135.56% Average Volume645.24 K
New High New Low


2019-12-06 16:30:40 | Bluebird, Celgene Cancer Therapy Gets Boost From New Study

2019-12-06 16:16:00 | Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

2019-12-06 09:15:02 | Stocks Rebound and Hang Onto Recent Gains

2019-12-03 08:52:01 | Are Options Traders Betting on a Big Move in bluebird BLUE Stock?

2019-12-02 07:30:00 | bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology ASH Annual Meeting

2019-11-27 03:28:08 | Global Blood's GBT Oxbryta Secures FDA Approval for SCD

2019-11-26 09:19:00 | Bluebird Bio Stock Is Rising as Analyst Cites Room for Gains

2019-11-19 10:46:45 | CRISPR Therapeutics stock jumps on early gene editing data

2019-11-18 09:36:02 | Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

2019-11-12 07:00:00 | bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

2019-11-08 14:20:35 | FDA approves Acceleron's blood disorder drug ahead of schedule

2019-11-07 06:08:01 | These 36 Mass. firms made Deloitte's Technology Fast 500

2019-11-06 09:00:00 | bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

2019-11-03 08:03:00 | Companies Like bluebird bio NASDAQ:BLUE Are In A Position To Invest In Growth

2019-10-31 17:35:09 | Bluebird Bio BLUE Reports Q3 Loss, Misses Revenue Estimates

2019-10-31 16:05:00 | bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

2019-10-31 10:33:02 | Analysts Estimate Bluebird Bio BLUE to Report a Decline in Earnings: What to Look Out for

2019-10-23 16:30:00 | bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

2019-10-22 07:30:00 | European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

2019-10-18 11:22:28 | New Gilead CFO: Let's Make a Deal

2019-10-17 10:30:27 | What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One

2019-10-15 11:01:11 | Is bluebird bio Inc BLUE Going To Burn These Hedge Funds ?

2019-10-11 12:49:04 | Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment

2019-10-10 11:17:03 | bluebird Inks Genome Editing Research Deal With Novo Nordisk

2019-10-09 08:00:00 | bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

2019-10-03 15:02:17 | 3 Cancer-Fighting Drug Stocks to Buy Right Now

2019-10-01 13:48:06 | Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio

2019-10-01 05:52:26 | LabCentral gets state, private funds for new biomanufacturing lab space

2019-09-27 07:00:00 | bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

2019-09-19 09:57:05 | Is There An Opportunity With bluebird bio, Inc.'s NASDAQ:BLUE 48% Undervaluation?

2019-09-18 09:25:00 | bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy CALD at the 13th European Pediatric Neurology Society EPNS Congress

2019-09-09 13:33:00 | Here's Why bluebird bio Fell 21.3% in August

2019-09-06 11:53:03 | FDA Grants Priority Review to Global Blood's SCD Candidate

2019-08-31 09:31:01 | Bluebird BLUE Down 19.4% Since Last Earnings Report: Can It Rebound?

2019-08-22 16:05:00 | bluebird bio Announces Investor Events in September

2019-08-22 02:18:27 | Massachusetts-based biotech company opens office in Eastlake neighborhood Photos

2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say

2019-08-12 16:16:47 | Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover'

2019-08-12 10:30:00 | Bluebird Bio Stock Down as Analyst Raises Worries About Zynteglo Launch

2019-08-12 07:38:00 | Bluebird Bio Drops Following William Blair Downgrade

2019-08-08 10:25:53 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?

2019-08-07 17:30:00 | bluebird bio Prepares for Launch

2019-08-02 11:12:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Beat

2019-08-01 19:45:11 | Bluebird Bio BLUE Reports Q2 Loss, Tops Revenue Estimates

2019-08-01 16:36:00 | bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress

2019-07-25 10:33:02 | Analysts Estimate Bluebird Bio BLUE to Report a Decline in Earnings: What to Look Out for

2019-07-15 14:46:29 | Biotech investors Wellington, RA Capital’s new funds top $700 million

2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now

2019-07-09 13:58:30 | 5 Immunotherapy Stocks to Keep a Close Eye On

2019-07-07 12:13:00 | Is bluebird bio a Buy?